FF Inhalation Powder

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 3

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01053988

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2009-10-05End: 2011-04-14Updated: 2018-07-12

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01054885

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2009-10-19End: 2011-02-08Updated: 2018-01-24

Related Papers

A Combined Model‐Based Meta‐Analysis of Aggregated and Individual <scp>FEV1</scp> Data From Randomized <scp>COPD</scp> Trials

CPT Pharmacometrics & Systems Pharmacology2025-06-19

Genetic evaluation of the effect of GLCCI1 rs37973 on corticosteroid response in chronic obstructive pulmonary disease

COPD Research and Practice2017-01-176 citations

A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.

2013-01-2371 citations

Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.

2013-01-1687 citations